🎉 M&A multiples are live!
Check it out!

Intellia Therapeutics Valuation Multiples

Discover revenue and EBITDA valuation multiples for Intellia Therapeutics and similar public comparables like Pharming, Julphar, and Benevolent AI.

Intellia Therapeutics Overview

About Intellia Therapeutics

Intellia Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It’s evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.


Founded

2014

HQ

United States of America
Employees

403

Website

intelliatx.com

Financials

LTM Revenue $55.5M

LTM EBITDA -$497M

EV

$385M

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Intellia Therapeutics Financials

Intellia Therapeutics has a last 12-month revenue of $55.5M and a last 12-month EBITDA of -$497M.

In the most recent fiscal year, Intellia Therapeutics achieved revenue of $57.9M and an EBITDA of -$524M.

Intellia Therapeutics expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See Intellia Therapeutics valuation multiples based on analyst estimates

Intellia Therapeutics P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue $36.3M $57.9M XXX XXX XXX
Gross Profit n/a n/a XXX XXX XXX
Gross Margin NaN% NaN% XXX XXX XXX
EBITDA -$506M -$524M XXX XXX XXX
EBITDA Margin -1396% -905% XXX XXX XXX
Net Profit -$474M -$481M XXX XXX XXX
Net Margin -1307% -831% XXX XXX XXX
Net Debt n/a n/a XXX XXX XXX

Financial data powered by Morningstar, Inc.

Intellia Therapeutics Stock Performance

As of April 15, 2025, Intellia Therapeutics's stock price is $8.

Intellia Therapeutics has current market cap of $776M, and EV of $385M.

See Intellia Therapeutics trading valuation data

Intellia Therapeutics Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
$385M $776M XXX XXX XXX XXX $-5.09

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

Intellia Therapeutics Valuation Multiples

As of April 15, 2025, Intellia Therapeutics has market cap of $776M and EV of $385M.

Intellia Therapeutics's trades at 6.9x LTM EV/Revenue multiple, and -0.8x LTM EBITDA.

Analysts estimate Intellia Therapeutics's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for Intellia Therapeutics and 10K+ public comps

Intellia Therapeutics Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV $385M XXX XXX XXX
EV/Revenue 6.7x XXX XXX XXX
EV/EBITDA -0.7x XXX XXX XXX
P/E -1.5x XXX XXX XXX
P/E/Growth n/a XXX XXX XXX
EV/FCF -1.1x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Intellia Therapeutics Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

Intellia Therapeutics Valuation Multiples

Intellia Therapeutics's NTM/LTM revenue growth is -14%

Intellia Therapeutics's revenue per employee for the last fiscal year averaged $0.1M, while opex per employee averaged $1.5M for the same period.

Over next 12 months, Intellia Therapeutics's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate Intellia Therapeutics's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for Intellia Therapeutics and other 10K+ public comps

Intellia Therapeutics Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth 60% XXX XXX XXX XXX
EBITDA Margin -905% XXX XXX XXX XXX
EBITDA Growth 3% XXX XXX XXX XXX
Rule of 40 (SaaS-only) -920% XXX XXX XXX XXX
Revenue per Employee $0.1M XXX XXX XXX XXX
Opex per Employee $1.5M XXX XXX XXX XXX
S&M Expenses to Revenue n/a XXX XXX XXX XXX
G&A Expenses to Revenue 217% XXX XXX XXX XXX
R&D Expenses to Revenue 806% XXX XXX XXX XXX
Opex to Revenue 1023% XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

Intellia Therapeutics Public Comps

See public comps and valuation multiples for Drug Development & Therapeutics and Regenerative Medicine comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Julphar XXX XXX XXX XXX XXX XXX
Benevolent AI XXX XXX XXX XXX XXX XXX
Galapagos XXX XXX XXX XXX XXX XXX
Pharming XXX XXX XXX XXX XXX XXX
Vivoryon Therapeutics XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

Intellia Therapeutics M&A and Investment Activity

Intellia Therapeutics acquired  XXX companies to date.

Last acquisition by Intellia Therapeutics was  XXXXXXXX, XXXXX XXXXX XXXXXX . Intellia Therapeutics acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by Intellia Therapeutics

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About Intellia Therapeutics

When was Intellia Therapeutics founded? Intellia Therapeutics was founded in 2014.
Where is Intellia Therapeutics headquartered? Intellia Therapeutics is headquartered in United States of America.
How many employees does Intellia Therapeutics have? As of today, Intellia Therapeutics has 403 employees.
Who is the CEO of Intellia Therapeutics? Intellia Therapeutics's CEO is Dr. John M. Leonard, M.D..
Is Intellia Therapeutics publicy listed? Yes, Intellia Therapeutics is a public company listed on NAS.
What is the stock symbol of Intellia Therapeutics? Intellia Therapeutics trades under NTLA ticker.
When did Intellia Therapeutics go public? Intellia Therapeutics went public in 2016.
Who are competitors of Intellia Therapeutics? Similar companies to Intellia Therapeutics include e.g. Julphar, Benevolent AI, Galapagos, Pharming.
What is the current market cap of Intellia Therapeutics? Intellia Therapeutics's current market cap is $776M
What is the current revenue of Intellia Therapeutics? Intellia Therapeutics's last 12-month revenue is $55.5M.
What is the current EBITDA of Intellia Therapeutics? Intellia Therapeutics's last 12-month EBITDA is -$497M.
What is the current EV/Revenue multiple of Intellia Therapeutics? Current revenue multiple of Intellia Therapeutics is 6.9x.
What is the current EV/EBITDA multiple of Intellia Therapeutics? Current EBITDA multiple of Intellia Therapeutics is -0.8x.
What is the current revenue growth of Intellia Therapeutics? Intellia Therapeutics revenue growth between 2023 and 2024 was 60%.
Is Intellia Therapeutics profitable? Yes, Intellia Therapeutics is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.